Study on the predictive value of pretreatment peripheral blood inflammatory markers regarding immunotherapy in patients with inoperable advanced or locally advanced oesophageal squamous cell carcinoma

Maodong Fu ^1,2, Zhiyong Li ^2,3, Jun Ma ^1,2

⁰Department of Integrative Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, People's Republic of China.

Scandinavian Journal of Gastroenterology +

|

February 16, 2024

View abstract on PubMed

Summary

Pretreatment immune-inflammation values like PIV, SII, and NLR predict immunotherapy effectiveness in esophageal cancer. High SII (≥834.295) indicates a poor prognosis, highlighting its role as an independent risk factor for survival.

Area Of Science

Oncology
Immunotherapy
Biomarkers

Background

Esophageal squamous cell carcinoma (ESCC) is a significant cause of cancer mortality.
Immunotherapy has emerged as a promising treatment for advanced ESCC, but predicting patient response remains challenging.
Pretreatment immune-inflammation markers may offer insights into treatment efficacy.

Purpose Of The Study

To evaluate the predictive and prognostic value of pretreatment peripheral blood immune-inflammation indices—pan-immune-inflammation value (PIV), systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR)—in patients with inoperable advanced or locally advanced ESCC receiving immunotherapy.

Main Methods

Retrospective analysis of clinical data from 107 patients with inoperable advanced or locally advanced ESCC.
Determination of optimal cutoff values for PIV, SII, NLR, and PLR using receiver operating characteristic (ROC) curves.
Univariate and multivariate analyses to identify risk factors for immunotherapy outcomes.

Main Results

Pretreatment PIV, SII, and PLR demonstrated predictive value for immunotherapy efficacy.
Patients with PIV ≥415.885, SII ≥834.295, and NLR ≥3.740 exhibited lower objective response rates (ORR) and disease control rates (DCR).
Elevated PIV, SII, and NLR were associated with shorter progression-free survival (PFS) and overall survival (OS). Tumor stage and SII were identified as independent risk factors for PFS and OS.

Conclusions

Peripheral blood PIV, SII, and NLR are valuable predictors of immunotherapy outcomes in advanced ESCC.
SII ≥834.295 is indicative of a poor prognosis following immunotherapy.
SII is an independent risk factor influencing survival in these patients.

Keywords:

Oesophageal squamous cell carcinoma (ESCC) immunotherapy peripheral blood inflammatory markers prognosis

Related Concept Videos

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.